Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired bloodbrain barrier integrity

World Journal of Biological Psychiatry

Volumn 13, Issue 7, 2012, Pages 482-492

  Steiner, Johann ^a,b,c   Bogerts, Bernhard ^a   Sarnyai, Zoltán ^b,c   Walter, Martin ^a   Gos, Tomasz ^a,d   Bernstein, Hans Gert ^a   Myint, Aye Mu ^a,e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PEMBROKE COLLEGE   (United Kingdom)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bloodbrain barrier; Glutamate; Kynurenines; Major depression; Psychoimmunology; Schizophrenia

Indexed keywords

GLUTAMIC ACID; KETAMINE; KYNURENIC ACID; KYNURENINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOLINIC ACID;

ASTROCYTE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGY; INFLAMMATION; MAJOR DEPRESSION; MICROGLIA; MONOCYTE; NEUROTRANSMISSION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

BLOOD-BRAIN BARRIER; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HUMANS; INFLAMMATION; KYNURENINE; NEUROGLIA; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84866275034     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.583941     Document Type: Review

References (119)

1. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. 2007. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185. (Pubitemid 46177578)
2. Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han LY, Choi C. 1998. Absence of neuroDEgeneration and neural injury in the cerebral cortex in a sample of elDErly patients with schizophrenia. Arch Gen Psychiatry 55:225-232.
3. Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F. 2000. Reduced glutamate in the anterior cingulate cortex in Depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47:305-313. (Pubitemid 30109243)
4. Axelsson R, Martensson E, Alling C. 1982. Impairment of the blood-brain barrier as an aetiological factor in paranoid psychosis. Br J Psychiatry 141:273-281. (Pubitemid 12052487)
5. Bayer TA, Buslei R, Havas L, Falkai P. 1999. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271:126-128. (Pubitemid 29400683)
6. Bechmann I, Galea I, Perry VH. 2007. What is the blood-brain barrier (not)? Trends Immunol 28:5-11. (Pubitemid 46001619)
7. Bechter K. 2004. [The mild encephalitis-hypothesis-new findings and studies]. Psychiatr Prax 31(Suppl 1):S41-43.
8. Beckmann M, Johansen-Berg H, Rushworth MF. 2009. Connectivity-based parcellation of human cingulate cortex and its relation to functional specialization. J Neurosci 29:1175-1190.
9. BenDEr DA, McCreanor GM. 1985. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 13:441-443. (Pubitemid 15096209)
10. Bernstein HG, Steiner J, Bogerts B. 2009. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 9:1059-1071.
11. Bluthe RM, Walter V, Parnet P, Laye S, Lestage J, Verrier D, et al. 1994. LipopolysacchariDE induces sickness behaviour in rats by a vagal mediated mechanism. CR Acad Sci III 317:499-503. (Pubitemid 24220250)
12. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L. 2002. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 168:3667-3674. (Pubitemid 34250439)
13. Chiarugi A, Calvani M, Meli E, Traggiai E, Moroni F. 2001. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-Derived macrophages. J Neuroimmunol 120:190-198. (Pubitemid 33016739)
14. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. 2005. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in Depression. Proc Natl Acad Sci USA 102:15653-15658. (Pubitemid 41528111)
15. Conejero-Goldberg C, Torrey EF, Yolken RH. 2003. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr Res 60:65-69. (Pubitemid 36018743)
16. Craddock RM, Lockstone HE, Rider DA, Wayland MT, Harris LJ, McKenna PJ, Bahn S. 2007. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS one 2:e692.
17. D'Mello C, Le T, Swain MG. 2009. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 29:2089-2102.
18. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. 2008. From inflammation to sickness and Depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46-56. (Pubitemid 350295688)
19. Doorduin J, DE Vries EF, Willemsen AT, DE Groot JC, Dierckx RA, Klein HC. 2009. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 50:1801-1807.
20. Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, Drexhage HA. 2010. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10:59-76.
21. Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. 2001. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96-98. (Pubitemid 32973903)
22. Falke E, Han LY, Arnold SE. 2000. Absence of neuroDEgeneration in the thalamus and caudate of elDErly patients with schizophrenia. Psychiatry Res 93:103-110. (Pubitemid 30139477)
23. Fellerhoff B, Laumbacher B, Mueller N, Gu S, Wank R. 2007. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry 12:264-272. (Pubitemid 46328502)
24. Galea I, Bechmann I, Perry VH. 2007. What is immune privilege (not)? Trends Immunol 28:12-18. (Pubitemid 44960159)
25. Gorwood P, Pouchot J, Vinceneux P, Puechal X, Flipo RM, DE Bandt M, Ades J. 2004. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 66:21-29. (Pubitemid 38030341)
26. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, et al. 2001. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78:842-853. (Pubitemid 32777985)
27. Guillemin GJ, Smith DG, Kerr SJ, Smythe GA, Kapoor V, Armati PJ, Brew BJ. 2000. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep 5:108-111. (Pubitemid 30488525)
28. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. 2005. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49: 15-23. (Pubitemid 40023649)
29. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. 2009. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 66:407-414.
30. Hashimoto K. 2009. Emerging role of glutamate in the pathophysiology of major Depressive disorder. Brain Res Rev 61: 105-123.
31. Heresco-Levy U, Javitt DC. 1998. The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8:141-152. (Pubitemid 28210341)
32. Kenis G, Maes M. 2002. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5: 401-412. (Pubitemid 35470359)
33. Kim JP, Choi DW. 1987. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 23:423-432. (Pubitemid 18004221)
34. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. 2009. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59:123-129.
35. Konradsson-Geuken A, Wu HQ, Gash CR, Alexander KS, Campbell A, Sozeri Y, et al. 2010. Cortical kynurenic acid bidirectionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169:1848-1859.
36. Kurumaji A, Wakai T, Toru M. 1997. DEcreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm 104:1361-1370. (Pubitemid 28031830)
37. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467. (Pubitemid 32830950)
38. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR. 2010. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major Depression. Behav Brain Res 210:84-91.
39. Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, et al. 2007. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 12:572-580. (Pubitemid 46816774)
40. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. 2010. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71: 138-149.
41. Lewitus GM, Schwartz M. 2009. Behavioral immunization: immunity to self-antigens contributes to psychological stress resilience. Mol Psychiatry 14:532-536.
42. Linderholm KR, Skogh E, Olsson SK, Dahl ML, Holtze M, Engberg G, et al. 2010. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull.
43. Lo JC, Huang WC, Chou YC, Tseng CH, Lee WL, Sun SH. 2008. Activation of P2X(7) receptors DEcreases glutamate uptake and glutamine synthetase activity in RBA-2 astrocytes via distinct mechanisms. J Neurochem 105:151-164. (Pubitemid 351444678)
44. Maeng S, Zarate CA Jr. 2007. The role of glutamate in mood disorders: results from the ketamine in major Depression study and the presumed cellular mechanism unDErlying its antidepressant effects. Curr Psychiatry Rep 9:467-474. (Pubitemid 350284937)
45. Maino K, Gruber R, Riedel M, Seitz N, Schwarz M, Müller N. 2007. T-and B-lymphocytes in patients with schizophrenia in acute psychotic Episode and the course of the treatment. Psychiatry Res 152:173-180. (Pubitemid 47212477)
46. Martins-DE-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, et al. 2010a. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44:1176-1189.
47. Martins-DE-Souza D, Schmitt A, Roder R, Lebar M, SchneiDEr-Axmann T, Falkai P, Turck CW. 2010b. Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J Psychiatr Res 44:989-991.
48. Miller AH. 2010. Depression and immunity: a role for T cells? Brain Behav Immun 24:1-8.
49. Miller AH, Maletic V, Raison CL. 2009. Inflammation and its discontents: the role of cytokines in the pathophysiology of major Depression. Biol Psychiatry 65:732-741.
50. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. 2004. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 15:618-629. (Pubitemid 38429977)
51. Miller CL, Llenos IC, Dulay JR, Weis S. 2006. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073-1074:25-37.
52. Miller CL, Llenos IC, Cwik M, Walkup J, Weis S. 2008. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem Int 52:1297-1303.
53. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. 2007. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:304-307. (Pubitemid 44959270)
54. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. 2008. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32:380-386. (Pubitemid 351178956)
55. Mossner R, Mikova O, Koutsilieri E, Saoud M, Ehlis AC, Muller N, et al. 2007. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in Depression. World J Biol Psychiatry 8:141-174. (Pubitemid 47163382)
56. Müller N. 2010. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11:31-42.
57. Müller N, Ackenheil M. 1998. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 22:1-33. (Pubitemid 28096427)
58. Müller N, Schwarz MJ 2008 A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major Depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258(Suppl 2):97-106. (Pubitemid 351758763)
59. Müller N, Myint AM, Schwarz MJ. 2009. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin Neurosci 11:319-332.
60. Myint AM, Kim YK. 2003. Cytokine-serotonin interaction through IDO: a neuroDEgeneration hypothesis of Depression. Med Hypotheses 61:519-525. (Pubitemid 37411894)
61. Myint AM, Leonard BE, Steinbusch HW, Kim YK. 2005. Th1, Th2, and Th3 cytokine alterations in major Depression. J Affect Disord 88:167-173. (Pubitemid 41266899)
62. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. 2007. Kynurenine pathway in major Depression: evidence of impaired neuroprotection. J Affect Disord 98: 143-151. (Pubitemid 46048912)
63. Nilsson LK, Linderholm KR, Engberg G, Paulson L, Blennow K, Lindstrom LH, et al. 2005. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80:315-322. (Pubitemid 41713657)
64. Okuda S, Nishiyama N, Saito H, Katsuki H. 1998. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell DEath with apoptotic features and region selectivity. J Neurochem 70:299-307. (Pubitemid 28020856)
65. Okusaga O, Yolken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, et al. 2011. Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. J Affect Disord 130:220-225.
66. Olney JW, Farber NB. 1995. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335-345. (Pubitemid 26007689)
67. Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
68. Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, Renshaw PF. 2008. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry 64:718-726.
69. Pae CU, Marks DM, Han C, Patkar AA. 2008. Does minocycline have antidepressant effect? Biomed Pharmacother 62:308-311. (Pubitemid 351749775)
70. Palomero-Gallagher N, Vogt BA, Schleicher A, Mayberg HS, Zilles K. 2009. Receptor architecture of human cingulate cortex: evaluation of the four-region neurobiological model. Hum Brain Mapp 30:2336-2355.
71. Papiol S, Molina V, Desco M, Rosa A, Reig S, Gispert JD, et al. 2005. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. Neuroimage 27:1002-1006. (Pubitemid 41317267)
72. Perkins MN, Stone TW. 1982. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247:184-187. (Pubitemid 12028646)
73. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801-808. (Pubitemid 351410515)
74. Prüss H, Dalmau J, Arolt V, Wandinger KP. 2010. Anti-NMDARezeptor- Enzephalitis: Ein interdisziplin ä res Krankheitsbild. Nervenarzt 81:396-408.
75. Quan N, Whiteside M, Herkenham M. 1998. Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysacchariDE. Neuroscience 83:281-293. (Pubitemid 28068057)
76. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. 2000. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:137-150. (Pubitemid 30106470)
77. Raison CL, Capuron L, Miller AH. 2006. Cytokines sing the blues: inflammation and the pathogenesis of Depression. Trends Immunol 27:24-31. (Pubitemid 43083561)
78. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. 2010. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and Depression. Mol Psychiatry 15:393-403.
79. Rajkowska G, Miguel-Hidalgo JJ. 2007. Gliogenesis and glial pathology in Depression. CNS Neurol Disord Drug Targets 6:219-233. (Pubitemid 46916253)
80. RieDEl M, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, Müller N. 2007. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 41:3-7. (Pubitemid 44708207)
81. Romeo HE, Tio DL, Rahman SU, Chiappelli F, Taylor AN. 2001. The glossopharyngeal nerve as a novel pathway in immune-tobrain communication: relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 115:91-100. (Pubitemid 32245657)
82. Rossi F, Schwarcz R, Rizzi M. 2008. Curiosity to kill the KAT (kynurenine aminotransferase): structural insights into brain kynurenic acid synthesis. Curr Opin Struct Biol 18:748-755.
83. Schwarcz R, Hunter CA. 2007. Toxoplasma gondii and schizophrenia: linkage through astrocyte-Derived kynurenic acid? Schizophr Bull 33:652-3.
84. Schwarcz R, Whetsell WO Jr, Mangano RM. 1983. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219:316-318. (Pubitemid 13222319)
85. Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. 2001. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521-30. (Pubitemid 32971883)
86. Schwarz MJ, Kronig H, Riedel M, Dehning S, Douhet A, Spellmann I, et al. 2006. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256:72-76.
87. Schwemmle M. 2001. Borna disease virus infection in psychiatric patients: are we on the right track? Lancet Infect Dis 1: 46-52. (Pubitemid 33586040)
88. Shalev H, Serlin Y, Friedman A. 2009. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009:278531.
89. Shirts BH, Wood J, Yolken RH, Nimgaonkar VL. 2006. Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. Schizophr Res 88:235-244. (Pubitemid 44693237)
90. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. 2009. Common variants conferring risk of schizophrenia. Nature 460:744-747.
91. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. 2008. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is Decreased in schizophrenia. Schizophr Res 103:71-82.
92. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, Bogerts B. 2006. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 112:305-316. (Pubitemid 44275885)
93. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. 2008. Immunological aspects in the neurobiology of suicide: Elevated microglial DEnsity in schizophrenia and Depression is associated with suicide. J Psychiatr Res 42:151-157. (Pubitemid 350061255)
94. Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, et al. 2010a. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci 260:509-518.
95. Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, Walter M, et al. 2010b. S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol (article ID 480707):11 pp.
96. Stevens B. 2008. Neuron-astrocyte signaling in the Development and plasticity of neural circuits. Neurosignals 16:278-288.
97. Stone JM, Morrison PD, Pilowsky LS. 2007. Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review. J Psychopharmacol 21:440-452. (Pubitemid 47077295)
98. Stone TW, Darlington LG. 2002. Endogenous kynurenines as targets for drug discovery and Development. Nat Rev Drug Discov 1:609-620. (Pubitemid 37361524)
99. Szymanski S, Ashtari M, Zito J, DEgreef G, Bogerts B, Lieberman J. 1991. Gadolinium-DTPA enhanced gradient echo magnetic resonance scans in first Episode of psychosis and chronic schizophrenic patients. Psychiatry Res 40:203-207.
100. Tanaka S, Matsunaga H, Kimura M, Tatsumi K, Hidaka Y, Takano T, et al. 2003. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 141:155-164. (Pubitemid 37289009)
101. Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K. 2000. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res 885:117-121.
102. Torrey EF, Albrecht P, Behr DE 1985. Permeability of the blood-brain barrier in psychiatric patients. Am J Psychiatry 142:657-658.
103. Torrey EF, Leweke MF, Schwarz MJ, Mueller N, Bachmann S, Schroeder J, et al. 2006. Cytomegalovirus and schizophrenia. CNS Drugs 20:879-85. (Pubitemid 44611137)
104. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. 2007. Antibodies to Toxoplasma gondii in patients with schizophrenia: a metaanalysis. Schizophr Bull 33:729-736. (Pubitemid 47343710)
105. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. 2006. Etanercept and clinical outcomes, fatigue, and Depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367:29-35. (Pubitemid 43038667)
106. Uranova NA, Zimina IS, Vikhreva OV, Krukov NO, Rachmanova VI, Orlovskaya DD. 2010. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry 11:567-578.
107. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, et al. 2008. Microglia activation in recentonset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820-822.
108. Vitkovic L, Konsman JP, Bockaert J, Dantzer R, Homburger V, Jacque C. 2000. Cytokine signals propagate through the brain. Mol Psychiatry 5:604-615.
109. Vollenweider FX, Kometer M. 2010. The neurobiology of psycheDElic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642-651.
110. Wagner-Jauregg J. 1887. Ü ber die Einwirkung fieberhafter Erkrankungen auf Psychosen. Allge Z Psychiatr 27:93-131.
111. Walter M, Henning A, Grimm S, Beck J, Schulte RF, Dydak U, et al. 2009. The relationship between aberrant neuronal activation patterns in the pregenual anterior cingulate, altered glutamatergic metabolism and anhedonia in Major Depression. Arch Gen Psychiatry 40:1482-1494.
112. Watanabe Y, Someya T, Nawa H. 2010. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 64:217-230.
113. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. 2005. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 43:81-89. (Pubitemid 40975402)
114. Wittchen ES. 2009. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci 14:2522-2545.
115. Wong ML, Dong C, Maestre-Mesa J, Licinio J. 2008. Polymorphisms in inflammation-related genes are associated with susceptibility to major Depression and antidepressant response. Mol Psychiatry 13:800-812.
116. Yang CR, Svensson KA. 2008. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 120:317-332.
117. Yolken RH, Torrey EF. 1995. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 8:131-145.
118. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, et al. 2011. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 258:686-688.
119. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. 2001. The relationship of Depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15:199-226. (Pubitemid 33070955)